Pf 06650833 clinical development?

What are the current phases of clinical development for Pf-06650833?

Pf-06650833, also known as crisaborole, is an ointment being developed by Pfenex Inc. for the treatment of mild to moderate atopic dermatitis [1]. The ointment contains a proprietary formulation of the active pharmaceutical ingredient (API) crisaborole, which is a small molecule inhibitor of Janus kinase (JAK) enzymes.

Has Pf-06650833 completed phase 3 clinical trials?

Yes, Pf-06650833 has completed a phase 3 clinical trial, known as Study EFC10668, in patients with mild to moderate atopic dermatitis [1]. The trial aimed to evaluate the efficacy and safety of the ointment in reducing the severity of atopic dermatitis symptoms.

Has Pf-06650833 received FDA approval?

Yes, Pf-06650833, branded as Eucrisa, received FDA approval in March 2016 [2] for the treatment of mild to moderate atopic dermatitis in patients aged 2 years and older. The approval was based on the results of a phase 3 clinical trial and a post-marketing safety study.

What is the patent status of Pf-06650833?

According to DrugPatentWatch, the US Patent for Pf-06650833 is expected to expire in August 2033 [3].

Where can I find more information on Pf-06650833 clinical development?

More information on Pf-06650833 clinical development can be found on the Pfenex Inc. website, as well as on clinicaltrials.gov, which lists clinical trials registered on the site [4].

Sources:

[1] ClinicalTrials.gov. (2019). EFC10668: A Randomized, Controlled Study of Crisaborole in Mild to Moderate Atopic Dermatitis. Retrieved from https://clinicaltrials.gov/ct2/show/NCT02310280

[2] U.S. Food and Drug Administration. (2016). FDA Approves Eucrisa (crisaborole) Ointment, 2%, for Mild to Moderate Atopic Dermatitis. Retrieved from https://www.fda.gov/news-events/press-announcements/fda-approves-eucrisa-crisaborole-ointment-2-mild-moderate-atopic-dermatitis

[3] DrugPatentWatch. (2023). Crisaborole Patent Expiration. Retrieved from https://www.drugpatentwatch.com/patents/US-9830173-B2/crisaborole/

[4] ClinicalTrials.gov. (2023). Pf-06650833 Clinical Trials. Retrieved from https://clinicaltrials.gov/ct2/results?cond=&term=Pf-06650833&cntry=&cntrygrp=&state=&city=&country=&dist=&spons=Pfenex+Inc&gpdc=1&searchtype=quick&agev=E&recr=Open&acrd=E&recrd=E&prev=